• +1-646-491-9876
    • +91-20-67278686

    Search

    Microscopic Polyangiitis-Pipeline Review H2 2017

    Microscopic Polyangiitis-Pipeline Review H2 2017

    • Report Code ID: RW0001881464
    • Category Life Sciences
    • No. of Pages 41
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Microscopic Polyangiitis (MPA)-Pipeline Review H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Microscopic Polyangiitis (MPA)-Pipeline Review H2 2017 provides an overview of the Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline landscape.

    Microscopic polyangiitis (MPA) is an uncommon disease. It is the result of blood vessel inflammation which can damage organ systems. The area most commonly affected by MPA includes the kidneys lung nerves skin and joints. Symptoms include shortness of breath or cough fever loss of appetite rashes muscle and/or joint pain. Treatment includes immunosuppressive medications.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Microscopic Polyangiitis (MPA)-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Microscopic Polyangiitis (MPA) (Cardiovascular) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.

    The Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Microscopic Polyangiitis (MPA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Phase III and Preclinical stages are 4 and 1 respectively.

    Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Microscopic Polyangiitis (MPA) (Cardiovascular) .
    - The pipeline guide reviews pipeline therapeutics for Microscopic Polyangiitis (MPA) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Microscopic Polyangiitis (MPA) (Cardiovascular) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Microscopic Polyangiitis (MPA) (Cardiovascular) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Microscopic Polyangiitis (MPA) (Cardiovascular)

    Reasons to buy

    - Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Microscopic Polyangiitis (MPA) (Cardiovascular) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Microscopic Polyangiitis (MPA)-Overview
    Microscopic Polyangiitis (MPA)-Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Microscopic Polyangiitis (MPA)-Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Microscopic Polyangiitis (MPA)-Companies Involved in Therapeutics Development
    Celltrion Inc
    ChemoCentryx Inc
    Coherus BioSciences Inc
    Sandoz International GmbH
    Teijin Pharma Ltd
    Microscopic Polyangiitis (MPA)-Drug Profiles
    avacopan-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    immune globulin (human)-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rituximab biosimilar-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rituximab biosimilar-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rituximab biosimilar-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Microscopic Polyangiitis (MPA)-Dormant Projects
    Microscopic Polyangiitis (MPA)-Product Development Milestones
    Featured News & Press Releases
    Jun 19 2017 Sandoz receives approval in Europe for Rixathon (biosimilar rituximab) to treat blood cancers and immunological diseases
    May 18 2017 Celltrion Healthcare Hungary Receives CHMP Positive Opinion for Blitzima (rituximab)
    Apr 21 2017 Sandoz Receives CHMP Positive Opinion For Rixathon (rituximab)
    Dec 15 2016 Celltrion Healthcare Hungary Receives CHMP Positive Opinion for Truxima
    Dec 04 2014 ChemoCentryx Granted EU Orphan Drug Designation for CCX168 an Orally Administered Complement C5a Receptor Inhibitor for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis Two Forms of ANCA-Associated Vasculitis
    Jun 03 2014 ChemoCentryx's CCX168 an Orally Administered Complement C5a Receptor Inhibitor Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Microscopic Polyangiitis (MPA) H2 2017
    Number of Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017
    Number of Products by Stage and Target H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Microscopic Polyangiitis (MPA)-Pipeline by Celltrion Inc H2 2017
    Microscopic Polyangiitis (MPA)-Pipeline by ChemoCentryx Inc H2 2017
    Microscopic Polyangiitis (MPA)-Pipeline by Coherus BioSciences Inc H2 2017
    Microscopic Polyangiitis (MPA)-Pipeline by Sandoz International GmbH H2 2017
    Microscopic Polyangiitis (MPA)-Pipeline by Teijin Pharma Ltd H2 2017
    Microscopic Polyangiitis (MPA)-Dormant Projects H2 2017

    List of Figures

    Number of Products under Development for Microscopic Polyangiitis (MPA) H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products by Targets H2 2017
    Number of Products by Stage and Targets H2 2017
    Number of Products by Mechanism of Actions H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    Celltrion Inc
    ChemoCentryx Inc
    Coherus BioSciences Inc
    Sandoz International GmbH
    Teijin Pharma Ltd

    Request for Sample

    Report Url https://www.reportsweb.com//microscopic-polyangiitis-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//microscopic-polyangiitis-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//microscopic-polyangiitis-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments